SNSE

0.2887

11.25% -0.0366

Vorhandelsmarkt: .29 0.0013 +0.45%

Sensei Biotherapeutics Inc (SNSE)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Schlusskurs vom Vortag:

$0.3253

Offen:

$0.3095

24-Stunden-Volumen:

543.84K

Relative Volume:

0.20

Marktkapitalisierung:

$7.26M

Einnahmen:

Nettoeinkommen (Verlust:

$-29.80M

KGV:

-0.2426

EPS:

-1.19

Netto-Cashflow:

$-25.19M

1W Leistung:

-43.20%

1M Leistung:

-34.01%

6M Leistung:

-42.27%

1J Leistung:

-70.84%

1-Tages-Spanne:

$0.2887

$0.3443

1-Wochen-Bereich:

$0.25

$0.4998

52-Wochen-Spanne:

$0.25

$1.94

Sensei Biotherapeutics Inc Stock (SNSE) Company Profile

Firmenname

Sensei Biotherapeutics Inc

Sektor

Healthcare (1162)

Branche

Biotechnology (673)

Telefon

(240) 243-8000

Adresse

1405 RESEARCH BLVD, SUITE 125, ROCKVILLE

Mitarbeiter

Twitter

Nächster Verdiensttermin

2025-03-28

Neueste SEC-Einreichungen

SNSE's Discussions on Twitter

Vergleichen Sie SNSE mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SNSE Sensei Biotherapeutics Inc	0.2887	7.26M	0	-29.80M	-25.19M	-1.19
VRTX Vertex Pharmaceuticals Inc	474.62	121.88B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	573.45	62.69B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	555.11	33.86B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	235.74	30.51B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	238.51	25.69B	3.81B	-644.79M	-669.77M	-6.24

Sensei Biotherapeutics Inc Stock (SNSE) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-05-14	Eingeleitet	Stephens	Overweight
2021-07-01	Herabstufung	Berenberg	Buy → Hold
2021-06-29	Herabstufung	Oppenheimer	Outperform → Perform
2021-03-01	Eingeleitet	Berenberg	Buy
2021-03-01	Eingeleitet	Citigroup	Buy
2021-03-01	Eingeleitet	Oppenheimer	Outperform
2021-03-01	Eingeleitet	Piper Sandler	Overweight

Alle ansehen

Sensei Biotherapeutics Inc Aktie (SNSE) Neueste Nachrichten

Apr 03, 2025

Penny Stocks To Add to Your WatchlistMarch 30th - MarketBeat

Apr 03, 2025

Apr 02, 2025

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference - The Manila Times

Apr 02, 2025

Promising Penny Stocks To ResearchMarch 29th - MarketBeat

Apr 02, 2025

Best Penny Stocks To Follow NowMarch 28th - MarketBeat

Apr 02, 2025

Mar 31, 2025

Sensei Biotherapeutics stock hits 52-week low at $0.34 By Investing.com - Investing.com South Africa

Mar 31, 2025

Sensei Biotherapeutics stock hits 52-week low at $0.34 - Investing.com

Mar 31, 2025

Mar 30, 2025

HC Wainwright Reiterates Buy Rating for Sensei Biotherapeutics (NASDAQ:SNSE) - Defense World

Mar 30, 2025

Sensei Biotherapeutics (NASDAQ:SNSE) Price Target Raised to $4.00 at Oppenheimer - Armenian Reporter

Mar 30, 2025

Sensei Biotherapeutics (NASDAQ:SNSE) Stock Price Expected to Rise, Oppenheimer Analyst Says - Defense World

Mar 30, 2025

Mar 29, 2025

Sensei Biotherapeutics Reports Promising 2024 Results - TipRanks

Mar 29, 2025

Mar 28, 2025

Sensei Biotherapeutics (SNSE) Reports Annual Loss and Decline in Cash Reserves - GuruFocus

Mar 28, 2025

Sensei stock holds Buy rating, $4 target from H.C. Wainwright By Investing.com - Investing.com Australia

Mar 28, 2025

Sensei Rockets on FY ’24 Results - Baystreet.ca

Mar 28, 2025

Sensei Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com

Mar 28, 2025

Sensei Biotherapeutics Reports Favorable Initial Clinical Activity Data For Solnerstotug In Resistant Tumors - Benzinga

Mar 28, 2025

Sensei Biotherapeutics price target raised to $4 from $3.50 at Oppenheimer - TipRanks

Mar 28, 2025

Oppenheimer Adjusts Price Target on Sensei Biotherapeutics to $4 From $3.50, Maintains Outperform Rating - Marketscreener.com

Mar 28, 2025

Sensei stock holds Buy rating, $4 target from H.C. Wainwright - Investing.com India

Mar 28, 2025

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress - GlobeNewswire

Mar 28, 2025

Breakthrough: Sensei's Cancer Drug Triples Response Rate in Hard-to-Treat Tumors - Stock Titan

Mar 28, 2025

Mar 27, 2025

Sensei Biotherapeutics announces initial results from solnerstotug trial portion - TipRanks

Mar 27, 2025

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data For Solnerstotug In PD-(L)1 Resistant Tumors - Marketscreener.com

Mar 27, 2025

Sensei Biotherapeutics : Company Presentation March 2025 - Marketscreener.com

Mar 27, 2025

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors - GlobeNewswire

Mar 27, 2025

Revolutionary Cancer Treatment Triples Response Rate in Hard-to-Treat Tumors: Clinical Trial Results Revealed - Stock Titan

Mar 27, 2025

Mar 21, 2025

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Sees Large Drop in Short Interest - Defense World

Mar 21, 2025

Mar 07, 2025

Sensei Biotherapeutics Stock Price, Quotes and Forecasts | NASDAQ:SNSE - Benzinga

Mar 07, 2025

Feb 24, 2025

Sensei Biotherapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView

Feb 24, 2025

Feb 19, 2025

Sensei Biotherapeutics (SNSE) to Release Quarterly Earnings on Wednesday - Defense World

Feb 19, 2025

Feb 07, 2025

What Makes Sensei Biotherapeutics (SNSE) a New Buy Stock - MSN

Feb 07, 2025

Feb 06, 2025

A stock that deserves closer examination: Sensei Biotherapeutics Inc (SNSE) - US Post News

Feb 06, 2025

Feb 04, 2025

Sensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference - GlobeNewswire

Feb 04, 2025

Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference - The Manila Times

Feb 04, 2025

Biotech Spotlight: Sensei Bio Takes Center Stage at Major Healthcare Conference - StockTitan

Feb 04, 2025

Jan 27, 2025

Sensei Biotherapeutics, Inc. Appoints Robert Pierce as Chief Scientific Officer; Opens its Boston Office - Marketscreener.com

Jan 27, 2025

Jan 11, 2025

Sensei Biotherapeutics Inc Shares Rise 25.49% From The Lows – But Will They Continue? - Marketing Sentinel

Jan 11, 2025

Jan 10, 2025

Biotech Advances Breakthrough Cancer Treatment Results - Streetwise Reports

Jan 10, 2025

Sensei Biotherapeutics (NASDAQ:SNSE) Earns Buy Rating from HC Wainwright - Defense World

Jan 10, 2025

Jan 08, 2025

Sensei Biotherapeutics faces Nasdaq delisting risk By Investing.com - Investing.com Australia

Jan 08, 2025

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones - The Manila Times

Jan 08, 2025

Sensei Bio's Cancer Drug Shows Promise in Phase 1/2 Trial, Enrolls 45 Patients for VISTA Study - StockTitan

Jan 08, 2025

Sensei Biotherapeutics faces Nasdaq delisting risk - Investing.com

Jan 08, 2025

Nov 27, 2024

Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference - GlobeNewswire

Nov 27, 2024

Nov 18, 2024

Sensei Biotherapeutics Q3 2024 Results and Strategic Moves - TipRanks

Nov 18, 2024

Nov 15, 2024

Layoff Tracker: Sensei to Cut 46% of Workforce, Close Research Site - BioSpace

Nov 15, 2024

Nov 14, 2024

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire

Nov 14, 2024